9. Social Impact & Impact Investing
Bricopia's mission is to ensure that everyone can fairly share in the benefits of cell-and-gene therapy, not only those who can afford it today.
Cell-and-gene therapy is advancing rapidly, but it is extraordinarily expensive. As of 31 December 2024, eight CAR-T therapies had been FDA-approved, with efficacy reported above 90% in some blood cancers, alongside roughly 40 other approved cell therapies and 5,000+ ongoing clinical trials. The FDA is expected to approve 10 to 20 new cell therapies per year. Over the coming decades, cell therapy is poised to become central to oncology, regenerative medicine, and anti-aging.
Sector Indicators
| Indicator | Value |
|---|---|
| FDA-approved CAR-T therapies | 8 |
| Other approved cell therapies | 40+ |
| Ongoing clinical trials | 5,000+ |
| Typical cost per dose | $400k |
Most cell therapies cost more than US$400,000 per dose, beyond the reach of most middle-class families. The Bricopia Foundation is designed to provide donors with additional cell-therapy "major medical" insurance and to fund clinical research, so that the value created by tokenization flows back into making these treatments accessible.
The Long Horizon: Regenerative & Anti-Aging Medicine
Peer-reviewed work in Science (2014) and Nature (2015) on "young blood" and aging has spurred interest in the regenerative potential of stem cells. A HealthBanks-affiliated program, Boyalife, carried out an early human anti-aging clinical effort in a Cockayne-syndrome case, illustrating the kind of future clinical value that well-preserved biological assets may unlock.
Forward-looking statements regarding research and therapies are inherently uncertain. Nothing here is medical advice or a guarantee of clinical outcomes.